At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 118 enrolled
Drug / intervention
Elagolix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
In Brief
A Phase 2 clinical trial evaluating Elagolix and Placebo for Polycystic Ovary Syndrome. Completed, enrolled 118 participants across 54 sites in 2 countries.
Detailed Summary
This study will assess the potential impact of elagolix on disordered pituitary and ovarian hormones in women with polycystic ovary syndrome (PCOS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartAug 2019
Primary CompletionFeb 2021
TodayJul 2026
First PostedMay 15, 2019
Enrollment StartAug 12, 2019
Primary CompletionFeb 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.1 years ago
Interventions
Elagolixdrug
Capsule administered orally
Placebodrug
Capsule administered orally